Does CNSP pay a dividend and is it safe?

CNS Pharmaceuticals Inc. (CNSP) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / CNSP / dividends

LEXX (34) MTVA (31) UPC (33) IMRN (47) ⌘ Pro Terminal →

CNS Pharmaceuticals Inc. (CNSP) Dividend Safety Gauge & 10-Year DRIP Compounder

$4.39 -12.20% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.29

CNS Pharmaceuticals Inc. (CNSP) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • SELL / AVOID Cap $7.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CNSP Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CNSP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $4.39 (-12.20% 1D, market cap $7.3M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 5/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CNSP compare to LEXX and MTVA in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CNSP carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LEXX (Lexaria Bioscience Corp.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $7.4M) and MTVA (MetaVia Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $7.4M). Among the 5-stock peer group, CNSP leads on earnings multiple (N/A) while CNSP leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CNSP?

▼

Per CNSP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001729427), CNS Pharmaceuticals Inc. generated $44.8M in revenue (+7.3% YoY), -$16.0K in net income, and -$13.8M in free cash flow against $8.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $4.29 (-2.39%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-6.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE-6.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CNSP)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (43/100 Composite)

🔍 WHY CNSP SCORES 43/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+14/20 pts (33% of score)

FRED Regime × Technicals: 29% of 52W Range • RSI-14 at 49.3 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (23% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$5.35-6.7% Next Q

Q2 (-2Q)

Grade D$4.99+1.8% Next Q

Q3 (-1Q)

Grade D$5.08-13.6% Next Q

Current

Grade D-$4.39-6.7% Hist 90D α

Trajectory: C- (51) → D- (43)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CNSP Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CNSP currently carries a cautious 43/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.29) and Max Pain ($4.61) forces dealer call-delta covering toward $11.07.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CNSP• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CNSP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 43%NO 57%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.7K

Yr 1

$11.4K

Yr 2

$12.2K

Yr 3

$13.0K

Yr 4

$13.9K

Yr 5

$14.8K

Yr 6

$15.8K

Yr 7

$16.9K

Yr 8

$18.1K

Yr 9

$19.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CNSP)

✓Walkthrough of CNSP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CNSP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -44.01%▼ DESCENDING CHANNEL

2026-11-03O $4.77H $5.00L $4.39C $4.39VOL 52.9K

RES: $5.37SUP: $3.54SMA50: $5.29SMA200: $4.57

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CNSP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CNSP Butterfly Map → + Track CNSP →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +7.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CNSP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CNSP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CNSP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CNSP)

Health Care Rank #415 of 1015 ⚔️ LEXX vs CNSP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CNSP vs. LEXX, MTVA, UPC, IMRN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, CNS Pharmaceuticals Inc. (CNSP) ranks #415 by composite RQD confidence (43/100, grade D-) and #916 by equity capitalization ($7.3M). Within this direct 5-issuer industry benchmark cohort, CNSP leads on earnings valuation at N/A trailing P/E, while CNSP leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. IMRN currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with CNSP at 43/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CNSP ACTIVE CNS Pharmaceuticals Inc.	D-	43/100	—	—	-35.0%	-12.20%	$7.3M	Benchmark Subject
LEXX Lexaria Bioscience Corp.	E	34/100	—	96.0%	-35.0%	+4.30%	$7.4M	/lexx-vs-cnsp →
MTVA MetaVia Inc.	E	31/100	—	—	-35.0%	+4.46%	$7.4M	/mtva-vs-cnsp →
UPC Universe Pharmaceuticals Inc. (Class A)	E	33/100	—	35.3%	—	-1.34%	$7.5M	/upc-vs-cnsp →
IMRN Immuron Limited	D	47/100	—	—	—	+2.01%	$7.1M	/imrn-vs-cnsp →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001729427 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), CNS Pharmaceuticals Inc. (CNSP) reported GAAP revenue of $44.8M (+7.3% vs. FY2024 revenue of $41.7M , and -15.3% cumulative change since FY2023) , GAAP net income of -$16.0K, operating cash flow of -$13.8M, and free cash flow of -$13.8M (+19.2% YoY). On the balance sheet, CNSP closed FY2025 with $8.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$44.8M	-$16.0K	-$13.8M	-$13.8M	$8.6M	—
FY2024 (FY)	2024-12-31	$41.7M	-$14.9K	-$17.1M	-$17.1M	$8.7M	—
FY2023 (FY)	2023-12-31	$52.8M	-$18.9K	-$14.1M	-$14.1M	—	—

3. CNSP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CNSP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does CNSP compare to LEXX and MTVA in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for CNSP?

Where is CNSP trading relative to its 50-day, 200-day, and 52-week technical levels?

CNSP last traded at $4.39 (-12.20% on volume of 15,108 shares), positioning the stock -17.01% below its 50-day simple moving average ($5.29) and -3.94% below its 200-day simple moving average ($4.57). Across its 52-week range of $1.90 to $10.54, CNSP sits at the 28.8% percentile with a 14-day RSI of 49.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.84 to $4.94).

Direct Sub-Reports: CNSP RQD Cockpit CNSP 12M Forecast CNSP Earnings & Move CNSP Dividends & DRIP CNSP Insiders & 13F CNSP Whale Options CNSP Profit Sankey CNSP News & Why

ROARABLE RATING BRIEF • RQD 43/100 (D-) ✓ SEC XBRL & RQD VERIFIED

CNSP — CNS Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

CNS Pharmaceuticals Inc. (CNSP) earns a live Roarable RQD composite score of 43/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $4.39 (-12.20% 1D, market capitalization $7.3M).

Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
Whale 13F & Options Flow (8/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (14/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

CNS Pharmaceuticals Inc. (CNSP) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry.. The SEC financials report revenue of — for each period provided, so the company's commercial revenue generation is not evident in the source data.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), CNS Pharmaceuticals Inc. (CNSP) reported $44.8M in annual revenue (up from $41.7M in FY2024, +7.3% YoY) and -$16.0K in GAAP net income. Over the multi-year SEC filing window from FY2023 ($52.8M revenue, -$18.9K net income) through FY2025, CNSP scaled operating cash flow to -$13.8M and free cash flow to -$13.8M, backed by $8.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D- • RQD 43/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 8/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 8/20, sustained execution supports upside toward the upper end of the $1.90 – $10.54 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Sector correlation is limited to the liquidity-beta signal described above, which ties CNSP's price sensitivity to net liquidity conditions. Second-order bottlenecks cannot be identified from the provided data. The primary ripple a prospective investor should monitor is the sensitivity of a 6.00x liquidity beta to changes in the Fed-TGA-RRP plumbing, as reflected in the signal's headline and brief.

Key Question #1: Can CNSP sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $44.8M and free cash flow of -$13.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is CNSP's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CNSP Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for CNS Pharmaceuticals Inc. (CNSP) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CNSP Debate Forum (3) ↓

🟡 MARKET WIRE StockInvest.us • 22h ago

Cns Pharmaceuticals Stock Price Forecast. Should You Buy CNSP?

StockInvest.us report covering CNS Pharmaceuticals Inc. (CNSP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

CNS Pharmaceuticals, Inc. Estimates – NASDAQ:CNSP

TradingView report covering CNS Pharmaceuticals Inc. (CNSP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE kalkine.ca • 1d ago

Which Strategic Pivots Are Behind Wednesday's Movers? House of Doge (NASDAQ:HODO), CNS Pharmaceuticals (NASDAQ:CNSP) and More

kalkine.ca report covering CNS Pharmaceuticals Inc. (CNSP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Ethos Technologies Inc. (LIFE) Stock Price, News, Quote & History

Yahoo! Finance Canada report covering CNS Pharmaceuticals Inc. (CNSP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 1d ago

Largest Companies by Market Cap: U.S. Stocks

TradingKey report covering CNS Pharmaceuticals Inc. (CNSP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Viva Biotech Holdings (VB0.MU) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering CNS Pharmaceuticals Inc. (CNSP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 1d ago

Most Active Stocks Today: U.S. Market

TradingKey report covering CNS Pharmaceuticals Inc. (CNSP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

HCW Biologics Inc. (HCWB) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering CNS Pharmaceuticals Inc. (CNSP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CNSP Bull vs. Bear Conversation Board — What's Your Call at $4.39?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CNSP 🐻 33% BEARISH CONVICTION

SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $5.75 (+15.0%)

📌 Pinned Debate

Forensic balance sheet pillar scores 10/20 with cash of $7.2M and Debt/Equity of 0.5 providing some stability against cash burn.

Forensic balance sheet pillar scores 10/20 with cash of $7.2M and Debt/Equity of 0.5 providing some stability against cash burn.. When you look under the hood at CNSP, Fundamental Cash Engine is 6/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (8/20) has been quietly accumulating below $10.54. My 12M target is $5.75.

RetailWhale_TX 🐂 BULL

Both sides have a point here — CNSP's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $4.30 (-14.0%)

Spot @ $5.00

FCF yield is 0%, ROIC is -35%, and FY 2025 FCF was -$13.8M against $7.2M cash, with a Piotroski F-Score of 1/9.

FCF yield is 0%, ROIC is -35%, and FY 2025 FCF was -$13.8M against $7.2M cash, with a Piotroski F-Score of 1/9.. Look at the math on CNSP: paying current EV/EBITDA multiples for -35.0% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $4.40 before getting long.